Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced that its management team will participate in a fireside chat and one-on-one meetings at Cantor’s 2026 Global Healthcare Conference, scheduled for September 9-11, 2026, in New York. President and CEO Seth Lederman, M.D., will present on September 10 from 3:55 to 4:25 p.m. ET. A live webcast and replay will be accessible through the Investors section of the Tonix website.
This participation comes at a pivotal time for Tonix as it continues to build momentum following the approval of TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg), the first new treatment for fibromyalgia in over 15 years. The company is focused on central nervous system (CNS) and immunology treatments for areas with high unmet medical need. Tonix’s CNS commercial infrastructure supports its marketed products, including acute migraine treatments Zembrace SymTouch and Tosymra.
Beyond its current offerings, Tonix is actively expanding the potential of TONMYA through Phase 2 clinical trials evaluating its efficacy in major depressive disorder and acute stress disorder. The company’s CNS pipeline also includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare genetic disorder. In the immunology space, Tonix is advancing TNX-4800, a monoclonal antibody for Lyme disease prophylaxis, and TNX-1500, a third-generation CD40 ligand inhibitor intended to prevent kidney transplant rejection.
The company’s participation in the Cantor conference underscores its commitment to advancing innovative therapies and engaging with the investment community. Investors and industry observers will have the opportunity to gain insights into Tonix’s strategic direction and pipeline progress. The live webcast and subsequent replay will ensure broad access to the presentation, reflecting Tonix’s transparency and dedication to shareholder communication.
For more details about the conference or to access the webcast, interested parties can visit the Tonix website. The full press release is available at https://nnw.fm/hajiz. Additionally, the latest news and updates regarding TNXP can be found in the company’s newsroom at https://nnw.fm/TNXP.
Tonix Pharmaceuticals is a fully integrated, commercial-stage biotechnology company. Its product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and they have not been approved for any indication besides those explicitly stated. The company’s presence at this major healthcare conference highlights its ongoing efforts to address significant unmet medical needs and its potential for growth in the biotechnology sector.
